Publications by authors named "Milene Seauve"
Article Synopsis
- The study aims to assess the risk of global infections in patients with psoriatic arthritis (PsA) and axial spondyloarthritis who are treated with targeted therapies.
- They systematically reviewed data from 60 randomized controlled trials with over 20,000 patients to analyze the rates of infections linked to various treatments.
- Findings revealed a moderate increase in overall infection risk, particularly in patients with axial spondyloarthritis, mainly driven by the use of TNF and IL-17 inhibitors, but there was no notable increase in serious infections.
Objective: To estimate the incidence of infections among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), two distinct phenotypes included in the large group of spondyloarthritis (SpA), treated with tumour necrosis-factor-inhibitors, interleukin-17-inhibitors, Janus kinase-inhibitors, IL-23 or IL-12/23-inhibitors (IL-12/23i), phosphodiesterase 4-inhibitors or cytotoxic T-lymphocyte associated protein 4-Ig.
Methods: A meta-analysis of randomised controlled trials (RCTs), open-label extension and observational studies was conducted. Serious infections were defined as infections that were life-threatening, required intravenous antibiotics and/or hospitalisation.